Latest news with #ViewnVivo
The Age
3 days ago
- Business
- The Age
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Sydney Morning Herald
3 days ago
- Business
- Sydney Morning Herald
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
